thought leadership

Key Considerations When Partnering with a CDMO for Your Plasma-Derived Therapies

Plasma contains an array of beneficial constituents that, when purified and concentrated, can be administered as medicines to treat rare and complex diseases. The generation of complex plasma proteins is something that animals have developed over the course of evolution. For drug development, skill and expertise is required to isolate these proteins from the blood and purify them into commercially viable and effective concentrations – in a safe, controlled manner that does not damage or destroy their unique structure and properties.

In a recent article published in The Medicine Maker, experts from Emergent break down the qualities that make an ideal external partner for plasma- based protein manufacturing and discuss what questions to consider when selecting a CDMO. 

Read Article

 

 

Genetic Vaccine Platforms Demonstrate Their Potential

In a recent Pharmaceutical Technology article, Emergent experts provide their insights on selection of technologies for vaccine...

READ MORE

COVID-19: 'Pandemic-ready' set-up placing Emergent apart in CDMO Space

In a recent article with BioProcess International, Syed T. Husain, senior vice president & CDMO business unit head at Emergent...

READ MORE

Podcast: Understanding Today's Lipid-based Formulation Landscape

As a drug delivery system, lipid-based formulations provide improved stability of an API and allow for safe, efficient delivery...

READ MORE